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Abstract
The conventional wisdom is that cell-surface receptors interact with ligands expressed on other cells
to mediate cell-to-cell communication (trans interactions). Unexpectedly, it has recently been found
that two classes of receptors specific for MHC class I molecules not only interact with MHC class I
molecules expressed on opposing cells, but also with those on the same cell. These cis interactions
are a feature of immunoreceptors that inhibit, rather than activate, cellular functions. Here, we review
situations in which cis interactions have been observed, the characteristics of receptors that bind in
trans and cis, and the biological roles of cis recognition.
As their name indicates, MHC molecules were discovered and characterized based on their
role in inducing potent rejection of tissue grafts. However, the physiological role of MHC
molecules remained enigmatic until ground-breaking studies demonstrated the fundamental
importance of the MHC complex in T-cell-mediated immunity to infection1. A vast amount
of subsequent work elucidated how T-cell receptors (TCRs) recognize self MHC molecules in
complex with non-self peptides derived from microbial or other foreign proteins.
Transplantation biology provided early evidence for the existence of an alternative immune-
recognition strategy. The laws of transplantation predicted that tissue grafts were accepted as
long they displayed a subset of the recipient’s MHC alleles2. Indeed, MHC heterozygous
offspring from two mouse strains that differed at the MHC locus (F1 hybrids) accepted solid
tissue grafts from either parent. However, parental bone-marrow grafts were rejected by
irradiated F1 hybrid mice, a phenomenon termed hybrid resistance3. This observation
suggested a novel type of immune recognition, which was controlled by MHC genes. The basis
for this phenomenon remained obscure until several lines of research converged on the proposal
that the lack of (appropriate) MHC class I molecules on host cells resulted in natural killer
(NK)-cell-mediated rejection (the ‘missing-self’ hypothesis)4. Subsequent work showed that
NK cells expressed MHC-class-I-specific inhibitory receptors, which protected normal host
cells from NK-cell-mediated attack. Consequently, the loss of MHC class I molecules, which
arises owing to infection or transformation, and is likely selected for by cytolytic T cells,
renders host cells susceptible to NK-cell-mediated lysis, as inhibitory receptors are no longer
engaged. These studies led to the identification of families of MHC class I receptors expressed
by NK cells. Hybrid resistance was eventually explained by the selectivity of inhibitory
receptors for certain MHC class I alleles together with the differential expression of these
receptors by subsets of NK cells. As a consequence, a subset of NK cells in MHC heterozygous
e-mails: Werner.Held@licr.unil.ch; mariuzza@carb.nist.gov.
NIH Public Access
Author Manuscript
Nat Rev Immunol. Author manuscript; available in PMC 2008 July 30.
Published in final edited form as:
Nat Rev Immunol. 2008 April ; 8(4): 269–278.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
hosts may fail to engage parental MHC class I molecules5, which results in NK-cell-mediated
rejection of bone-marrow grafts.
‘Missing-self’ hypothesis
The concept that absence of MHC class I expression renders host cells sensitive to lysis by
natural killer cells.
Inhibitory NK-cell receptors specific for classical MHC class I molecules belong to the mouse
Ly49 (also known as KLRA) receptor family6,7 and the human killer immunoglobulin-like
receptor (KIR) family8-10. The molecular cloning of NK-cell receptors led to the identification
of additional MHC class I receptors, which had not been predicted on the basis of functional
experiments: human leukocyte immunoglobulin-like receptors (LILRs; also known as LIRs,
ILTs or MIRs), and their orthologues, mouse paired immunoglobulin-like receptors (PIRs), as
well as the heterodimeric CD94-NKG2 (NK group 2) receptors11-14 (TABLE 1).
All of these MHC class I receptors were identified based on their capacity to regulate immune-
cell function on binding in trans to MHC ligands expressed by other cells (antigen-presenting
cells (APCs) in the case of TCRs, and target cells in the case of NK-cell receptors). Recently,
however, the structurally unrelated NK-cell receptors Ly49 and LILRs or PIRs were found to
interact with MHC class I ligands expressed in the plane of the same membrane (in cis)15,
16. Here, we examine the possible structural basis for cis versus trans binding of MHC
molecules by these receptors and discuss the physiological relevance of cis and trans
interactions for immune-cell function. we further review evidence that some receptors that
recognize non-MHC ligands also act both in cis and trans, indicating that cis interactions may
need to be considered alongside conventional trans interactions in the functional analysis of
certain immunoreceptors.
MHC recognition in trans and cis
T-cell receptors
X-ray crystallographic studies of TCRs bound to peptide-MHC-class-I or peptide-MHC-class-
II complexes have shown that the TCR is typically positioned diagonally across the composite
surface created by the peptide and the MHC α-helices that flank the peptide-binding groove,
with the variable-α (vα) domain situated over the N-terminal half of the peptide and the vβ
domain over the C-terminal half17 (FIG. 1a). The affinity of this interaction determines the
fate of T cells during thymocyte development and the type of immune response that T cells
will elicit when mature. These effects are mediated by trans recognition of peptide-MHC
complexes expressed by stromal cells or APCs. Although T cells express MHC class I
molecules, this expression is not required for thymocyte positive selection18 or for the
activation of peripheral T cells19. Thus, there is no evidence that TCRs functionally interact
with MHC molecules in cis. Indeed, structural considerations would exclude this possibility,
as the segments connecting both TCR and MHC molecules to their respective transmembrane
domains appear too short (10-20 residues) to permit a TCR to engage an MHC molecule on
the same cell. Moreover, segmental flexibility between the vαvβ and CαCβ modules of the
TCR, as well as between the α1, α2 and α3 domains of an MHC class I molecule, is too restricted
to compensate for the shortness of the connecting peptides.
Positive selection
One step in the process of T-cell differentiation in the thymus. Thymocytes expressing T-
cell receptors with moderate affinity for self-peptide-MHC complexes receive a survival
signal and continue to develop towards becoming single positive (CD4+CD8- or
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CD4-CD8+) T cells. Positive selection is mediated by resident stromal cells in the thymic
cortex.
Ly49 receptors
Ly49 receptors are homodimeric type II membrane proteins, with each chain composed of a
C-type lectin-like domain (CTLD) connected by a stalk region of approximately 70 amino-
acid residues to transmembrane and cytoplasmic domains. The Ly49 receptor family comprises
at least 23 members in mice (Ly49A-Ly49w), 13 of which have an inhibitory function and 10
of which have an activating function20. This type of receptor is expressed by rodent but not
human NK cells, which instead express KIRs to monitor MHC class I expression. Different
Ly49 receptors exhibit distinct MHC-binding properties, ranging from the broad recognition
of MHC class I molecules by Ly49C to the allelic specificity of Ly49A21. Bound peptide is
necessary for MHC class I recognition by Ly49 receptors, although binding to Ly49A is
independent of the peptide sequence22. Conversely, the Ly49C and Ly49I receptors are peptide
selective, despite the absence of direct contacts with peptide23-26.
Type II membrane proteins
An integral membrane protein, such as Ly49, in which the carboxy terminus is extracellular.
C-type lectin-like domain
(CTLD). A protein module originally identified as a carbohydrate-recognition domain in a
family of calcium-dependent lectins. The natural-killer-cell receptor group of C-type lectin-
like receptors includes disulphide-linked homodimers or heterodimers that do not bind
calcium and recognize proteins instead of carbohydrates.
In contrast to TCRs, which dock onto the top of MHC molecules, structural and mutagenesis
studies of complexes of Ly49A with H2-Dd, and of Ly49C with H2-Kb, revealed that Ly49
receptors contact MHC class I molecules at a wide cavity underneath the peptide-binding
platform26-28. This binding site, which partially overlaps that of CD8 (REF. 29), is formed
by the α2 and α3 domains of MHC class I and β2-microglobulin (β2m). In the Ly49C-H2-Kb
complex26, the Ly49C homodimer engages H2-Kb bivalently, such that each CTLD makes
identical interactions with MHC class I to form a symmetrical, butterfly-shaped assembly (FIG.
1b). By contrast, in the Ly49A-H2-Dd complex28, the Ly49A dimer contacts H2-Dd
asymmetrically, with only one of its subunits binding an MHC molecule (FIG. 1c). A second
potential MHC-binding site, originally observed in the Ly49A-H2-Dd crystal structure27, was
ruled out as not functionally relevant by subsequent mutagenesis studies30,31. The structural
basis for the very different modes of MHC engagement in the Ly49C-H2-Kb and Ly49A-H2-
Dd complexes is dependent on the different geometries of the Ly49C and Ly49A dimers. The
Ly49C dimer adopts an ‘open’ conformation, in which the CTLD subunits are less closely
juxtaposed than in the Ly49A dimer, which adopts a ‘closed’ conformation (FIG. 1b,c).
Important steric clashes between MHC molecules would preclude the closed Ly49A dimer
from simultaneously binding two MHC in the manner of the open Ly49C dimer. However, a
nuclear magnetic resonance (NMR) study of unbound Ly49A revealed that the receptor exists
predominantly in the open state in solution, similar to Ly49C, and that the open form of Ly49A
can bind two MHC molecules32. Hence, Ly49A (and presumably other Ly49 receptors) can
assume both open and closed conformations, resulting in differential engagement of MHC
ligands that might correlate with trans and cis binding, respectively (see later).
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The capacity of Ly49A to bind H2-Dd on other cells differs markedly between NK cells from
mice that express H2-Dd and mice that lack H2-Dd expression33. This effect is due to the
expression of H2-Dd on the NK cells themselves, which masks Ly49A and reduces its capacity
to bind H2-Dd ligand on other cells15. Indeed H2-Dd occupies at least 75% of the Ly49A
molecules expressed by individual NK cells, reducing the accessibility of Ly49A by
approximately fourfold34,35. Similar to Ly49A, most other Ly49 receptors of known MHC
specificity have the capacity to interact with MHC class I molecules in cis25,36. The notable
exception is the more distantly related receptor Ly49B, which only binds MHC class I
molecules in trans25.
The inhibitory interaction of Ly49A with H2-Dd on target cells (trans interaction) uses a
binding site beneath the peptide-binding platform of H2-Dd (REFs 27,30,31). This same
binding site mediates the interaction with H2-Dd in cis15. Consequently, Ly49 receptors must
drastically reorient their CTLDs relative to the NK-cell surface to bind MHC class I in trans
versus cis (FIG. 2a,b). It is most likely that the exceptionally long stalk regions linking the
CTLDs of Ly49 molecules to the membrane provide the requisite flexibility. Although these
proline-rich stalks have not been visualized in any Ly49 structure, they are predicted to consist
of coiled-coil regions inter-spersed with several flexible segments that confer mobility to the
ectodomains27. Based on the structure of the Ly49C-H2-Kb complex26, the stalks must adopt
a back-folded, or bent, conformation for the Ly49 dimer to bind in trans, as the N-termini of
the CTLDs point away from the NK-cell membrane (FIG. 2a). Conversely, cis binding would
require the stalks to assume an extended conformation that orients the CTLDs with their N-
termini directed towards the NK cell (FIG. 2b). Although it is unknown whether one Ly49
dimer can bind two MHC class I molecules in cis, simple modelling suggests that engagement
of both CTLDs by MHC molecules on the NK cell is unlikely, owing to the orientation that
binding of one MHC molecule would impose on the Ly49 dimer (FIG. 2b). If so, the (bivalent)
Ly49C-H2-Kb and (monovalent) Ly49A-H2-Dd complexes would exemplify trans and cis
recognition, respectively.
LILRs and PIRs
After the C-type lectin-like Ly49 receptors, the immunoglobulin-like LILRs and PIRs were
the second class of immunoreceptors that were found to interact with MHC class I in cis16.
As LILRs and PIRs also recognize MHC class I in trans13, structurally unrelated receptors
have evolved corresponding capacities to bind MHC ligands expressed on the same membrane,
as well as on opposing membranes, indicating convergent evolution. This suggests that cis
recognition of MHC class I may be of general importance as a mechanism for regulating
immune-cell function (see later).
The human LILRs comprise at least five inhibitory receptors (LILRB1-LILRB5) and three
activating receptors (LILRA1-LILRA3), which are characterized by two or four extracellular
immunoglobulin-like domains13,37. The homologous mouse PIRs, which contain six
immunoglobulin-like domains, include a single inhibitory receptor (PIRB). At least six genes
encode activating receptors (PIRA)14,38. LILRB1 is broadly distributed, whereas LILRB2
and PIRB are more selectively expressed by B cells and myeloid cell types, but not by T cells
and NK cells. These receptors bind a wide range of classical and non-classical MHC class I
molecules with low affinity and without any apparent allelic specificity (reviewed in REF.
39).
Structural knowledge of LILRs and PIRs is based mainly on studies of LILRB1 (REF. 40).
MHC class I binding is mediated by the two most membrane-distal immunoglobulin-like
domains (D1 and D2) of this four immunoglobulin-like domain receptor. The structure of
LILRB1 (D1 and D2 only) in complex with HLA-A2 showed that LILRB1 binds at a site
formed by the α3 domain of HLA-A2 and β2m, such that the tip of D1 contacts the α3 domain
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and the D1-D2 interdomain hinge region contacts β2m (FIG. 1d). A significant contribution
by β2m, which was also observed for PIRB41, helps to explain the broad MHC reactivity of
LILRs and PIRs. Although the structure of the complete LILRB1 ectodomain (D1-D4) has not
been determined, modelling indicates that the four immunoglobulin-like domains must adopt
an extended conformation, similar to that reported for CD4 (REF. 42), to bind MHC class I on
an opposing cell surface (FIG. 2c).
A similarly broad MHC recognition profile in cis and trans16 provides circumstantial evidence
that the same binding site of LILRB2 mediates both interactions. If so, cis recognition would
require D1 and D2 to reverse direction with respect to the effector-cell surface, resulting in a
horseshoe-shaped configuration of D1-D4 in which LILRB1 bends back on itself (FIG. 2d).
Although such a large reversal implies considerable flexibility in the peptide segment
connecting D2 and D3, the structure of the N-terminal four immunoglobulin-like domains of
the Drosophila melanogaster protein DSCAM (Down syndrome cell-adhesion molecule)
showed a horseshoe arrangement, which is made possible by a five-residue hinge between the
D2 and D3 immunoglobulin-like domains of DSCAM, that is very similar to that proposed
here for cis-binding LILRB2 (REF. 43). In the case of PIRB, which has two more
immunoglobulin-like domains proximal to the membrane compared with LILRB2, additional
flexibility might derive from the D4-D5 or D5-D6 connecting segments. Thus, Ly49 receptors
and LILRs or PIRs appear to have evolved two distinct strategies to achieve cis and trans MHC
recognition: unusually long stalk regions in the case of Ly49 receptors, and very flexible (or
multiple) interdomain hinges in the case of LILRs and PIRs.
KIRs and CD94-NKG2
Human NK cells use KIRs to monitor MHC class I expression on target cells (reviewed in
REF. 44). These receptors, the role of which corresponds to that of Ly49 receptors in rodents,
comprise two or three extracellular immunoglobulin-like domains, and hence are designated
KIR2D and KIR3D, respectively. In contrast to both Ly49 receptors and LILRs, KIRs dock
onto the top of an MHC class I molecule in a manner that resembles that of TCR binding45,
46. There is currently no evidence that the function of KIR2DL is influenced by HLA-C
expression in cis (N. Gardiol and W.H., unpublished observations). KIR3D contains an
additional N-terminal immunoglobulin-like domain (D0), which enhances MHC class I
binding by the D1 and D2 domains47. A possible effect of a cis ligand on KIR3DL function
has not been tested.
The heterodimeric C-type lectin-like CD94-NKG2 receptors, which are expressed on NK cells
and some effector T cells, bind the non-classical human HLA-E or mouse Qa-1b
molecules11,12. Structural models based on the complex between NKG2D (NK group 2,
member D) and one of its ligands, MICA (MHC-class-I-polypeptide-related sequence A)48,
together with the structure of the CD94-NKG2 heterodimer49 and the role of specific residues
in HLA-e and its bound peptide on recognition49,50, suggest that CD94-NKG2 binds to the
α1-α2 platform domain of MHC class I, as do KIRs. Ligand binding by CD94-NKG2A is not
influenced by Qa-1b expression by NK cells (L. Scarpellino and W.H., unpublished
observations), suggesting that the inhibitory CD94-NKG2A receptor is not masked by cis
ligands.
HLA-E
A non-classical MHC class I molecule with limited sequence variability. Its expression on
the cell surface depends on the availability of peptides derived from the signal sequence of
classical MHC class I molecules. HLA-E is recognized by CD94-NKG2 receptors.
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Qa-1b
A functional mouse homologue of human HLA-E. similar to HLA-E, Qa-1b cell-surface
expression depends on the binding of peptides derived from the signal sequence of classical
MHC class I molecules and it is recognized by CD94-NKG2 receptors.
Although there is at present no evidence for cis recognition by inhibitory receptors that bind
to the top of MHC class I ligands (KIRs, CD94-NKG2), an unusual feature initially described
for the non-classical MHC molecule haemochromatosis protein (HFE) raises the formal
possibility of cis interactions for at least some of these receptors. HFE contributes to the
maintenance of iron homeostasis by binding to the transferrin receptor (TfR)51. The structure
of the complex between HFE and TfR indicates that these molecules associate in cis on the
same cell membrane, rather than in trans between opposing cell membranes52. To do so, HFE
‘lies down’ parallel to the cell membrane, to allow the HFE α-helices that form the peptide-
binding groove in classical MHC class I molecules to contact TfR (FIG. 1e). Interestingly,
HFE is recognized by αβ TCRs53, implying that it can also adopt an ‘upright’ configuration.
If classical MHC molecules can assume a lying down orientation under certain circumstances,
as has been suggested54, this may allow cis binding by immunoreceptors such as KIRs that
engage MHC class I ligands via their α1-α2 platform domain. Irrespective of this possibility,
however, the structure of the HFE-TfR complex52 suggests that cis association may predate
the immunological functions of MHC molecules.
Haemochromatosis protein
(HFE). A non-classical MHC class I molecule that regulates iron metabolism by binding to
the transferrin receptor. The HFE gene is mutated in hereditary haemochromatosis — an
iron overload disease.
Role of MHC class I recognition in cis
To date, cis interactions have been documented exclusively for MHC class I receptors with
inhibitory function. Such receptors are characterized by the presence of immunoreceptor
tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic domain. when phosphorylated
by SRC family tyrosine kinases, such as LCK or LYN, ITIMs recruit phosphatases, such as
SHP1 (SRC-homology 2 (SH2)-domain-containing protein tyrosine phosphatase 1), that
subsequently suppress phosphorylation-based activation signalling (reviewed in REF. 55).
Importantly, efficient ITIM phosphorylation, and consequently inhibitory signalling, requires
co-ligation of inhibitory receptor(s) with activating receptor(s)56. Accordingly, the role of
MHC class I recognition by inhibitory receptors in cis needs to be considered in the context of
the activation receptor(s) or pathways that are co-engaged.
Immunoreceptor tyrosine-based inhibitory motif
(ITIM). A short amino-acid sequence (the consensus sequence of which is Val/Ile-X-Tyr-
X-X-Val/Leu, where X denotes any amino acid) that is found in the cytoplasmic tail of
inhibitory receptors. ITIMs are thought to mediate inhibitory signalling by recruiting
phosphatases such as SHP1 (SRC-homology-2-domain-containing protein tyrosine
phosphatase 1).
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Ly49: regulation of NK-cell effector function
NK cells have essential direct and indirect roles in innate defence against infection and
transformed cells. In response to diseased (as well as to normal) host cells, multiple distinct
activation receptors induce the exocytosis of cytolytic granules and the production of
immunoregulatory cytokines by NK cells. Inhibitory receptors, many of which are specific for
MHC class I, counteract NK-cell activation. Target-cell lysis occurs when NK-cell activation
exceeds inhibition signalling57. Consequently, inhibitory signals set the activation threshold
required for NK-cell-mediated target-cell lysis.
Co-expression of Ly49A and H2-Dd on the NK-cell membrane does not lead to constitutive
ITIM phosphorylation (L. Scarpellino and W.H., unpublished observations) and there is no
evidence that the functionality of these NK cells is impaired15, indicating that Ly49A cis
interactions do not generate tonic inhibition signals. Rather, the H2-Dd on the NK cells
sequesters a significant fraction of Ly49A receptors, and this restricts the pool of Ly49A
receptors that are available for functional interaction with MHC class I ligands on target cells.
This is apparent at the site of NK-cell-target-cell contact, the so-called immunological synapse.
when NK cells do not express H2-Dd themselves, Ly49A is efficiently recruited to the NK-
cell synapse by the H2-Dd expressed on target cells34,58. By contrast, Ly49A accumulation
is strongly reduced when NK cells express H2-Dd, suggesting that only the initially accessible
Ly49A receptors can be recruited to the NK-cell synapse and that trans H2-Dd cannot compete
with cis H2-Dd for Ly49A binding. This restricts the inhibitory capacity of Ly49A in the context
of H2-Dd expression15,33.
Immunological synapse
A term derived from the similiarities to the synapses that occur in the nervous system, it
defines a region that can form at the cell surface between two cells of the immune system
that are in close contact, such as the interaction between a T cell and a natural killer cell
with an antigen-presenting cell and a target cell, respectively. This interface involves
adhesion molecules, as well as antigen receptors and cytokine receptors.
The moderation of the inhibitory signalling capacity renders NK cells more useful, as the
activation threshold required for target-cell lysis is lowered. As an example, stress-associated
expression of NKG2D ligands by host cells enhances NK-cell activation signalling. This is
sufficient to induce target-cell lysis when NK-cell inhibition is moderate (FIG. 3a) but it may
be insufficient when NK-cell inhibition is too potent (FIG. 3b). Likewise, when the number of
available inhibitory receptors is limited, even a minor reduction of MHC class I ligand
expression by host cells is sufficient to abrogate NK-cell inhibition and consequently lead to
target-cell lysis59. Thus, the restriction of inhibitory signalling by cis interaction considerably
improves the sensitivity of NK cells to react to diseased host cells. Despite the predominance
of sequestered Ly49A, the number of residual Ly49A receptors that can functionally interact
in trans is sufficient to prevent auto-aggression of non-stressed host cells expressing MHC
class I molecules at physiological levels33,60.
LILRB2 and PIRB: regulators of mast-cell effector function
Mast cells have essential protective roles in IgE-mediated immune responses, such as host
protection against parasites. Mast cells are activated by the high-affinity Fc receptor for IgE
(FcεRI), when bound IgE is crosslinked by multivalent antigens. Mast-cell activation triggers
mast-cell degranulation, releasing vasoactive amines, such as histamine, and induces the
synthesis of pro-inflammatory molecules and cytokines. excessive or aberrant mast-cell
activation is associated with allergic reactions (reviewed in REF. 61).
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Similar to NK cells, mast-cell activation is counter-regulated by several distinct inhibitory
receptors, including PIRB16,62. Indeed, PIRB engagement by MHC class I dampens mast-
cell activation16 (FIG. 3c). Cell mixing experiments have shown that mast-cell activation is
not significantly attenuated when the PIRB-MHC class I interaction occurs exclusively in
trans16. The inhibitory effect of PIRB on mast-cell activation therefore depends on MHC class
I recognition in cis (FIG. 3d). even in the absence of deliberate mast-cell activation, PIRB is
constitutively tyrosine phosphorylated and associated with SHP1 (REFs 16,63). Thus, in
contrast to Ly49A, the PIRB-MHC class I cis interaction may generate cell-autonomous, tonic
inhibitory signals (FIG. 3c). Tonic suppression seems to prevent ‘spontaneous’ mast-cell
degranulation, which may occur by ‘accidental’ aggregation of FcεRI-bound IgE. MHC class
I expression in cis might lead to PIRB aggregation and/or, according to the concept of co-
ligation, mediate an association of PIRB with the activating receptor FcεRI.
The new findings regarding PIRB function in mast cells contrast with the role of LILRB1 and
LILRB2 in NK cells and myeloid cells, respectively, in which receptor engagement by HLA
ligands on other cells dampens cellular activation13,64. This provides evidence that the LILR
and PIR family receptors can also functionally interact with MHC class I molecules in trans.
The precise contribution of cis versus trans interactions involving LILRs and PIRs to inhibitory
signalling therefore warrants further investigation. Similar to CD22 (see later), recognition of
MHC class I by LILRs or PIRs in cis and/or in trans may depend on whether effector cells are
activated by cell-bound ligands as opposed to soluble ligands.
In addition to MHC class I, LILRB1 recognizes the MHC-class-I-like molecule UL18 encoded
by human cytomegalovirus (HCMV). Cis binding by LILRB2 raises the issue of whether UL18
interacts with LILRB1 on the surface of HCMV-infected cells. This could have a role for latent
HCMV infection, which is established in myeloid lineage cells65, which often express
LILRB1.
Siglecs: CD22 regulation of B-cell activation
Similar to the two-way recognition of MHC class I ligands, sialic-acid modifications of
glycoproteins or glycolipids are recognized in cis and trans by several Siglecs (sialic-acid-
binding immunoglobulin-like lectins). Siglecs are type I membrane proteins with an N-terminal
V-type immunoglobulin domain that binds sialic acids and variable numbers (1-16) of C-type
immunoglobulin domains (reviewed in REF. 66).
The most extensively characterized Siglec is CD22 (also known as Siglec-2), a negative
regulator of B-cell receptor (BCR) signalling. CD22 is a seven-immunoglobulin domain
receptor, which binds sialic acids linked to galactosidase (Sia α2-6Gal) typically found on N-
linked glycans of glycoproteins. In B cells, CD22 is largely inaccessible to soluble, multivalent
sialoside probes, owing to the interaction of CD22 in cis with sialic acids67,68. The crucial
sialic-acid-modified cis ligand is unknown, even though CD22 can bind to membrane IgM,
CD45 and CD22 itself. Access to the CD22 receptor is restored when sialic acids are removed
by sialidase treatment67, or in mice lacking the sialyltransferase ST6GAL1 (REF. 68).
In the absence of deliberate antigen exposure, basal BCR signalling is increased in B cells
lacking CD22, demonstrating that the primary function of CD22 is to dampen BCR
signalling69. The direct and/or indirect association of CD22 with the BCR complex in cis
therefore mediates tonic suppressive signals that prevent ‘spontaneous’ B-cell activation (FIG.
3e). On B-cell activation by soluble antigen, the CD22 ITIMs are phosphorylated by the BCR-
associated SRC-family kinase LYN. The ensuing recruitment of SHP1 to CD22 dampens BCR
signalling (FIG. 3f). CD22 variants that selectively lack sialic-acid-binding capacity mediate
reduced SHP1 recruitment to CD22, and consequently increased BCR signalling69,70. Thus,
direct or indirect association with the BCR complex in cis is essential for the inhibitory function
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of CD22. This is in contrast to Ly49 receptors, where cis association reduces the inhibitory
function.
In addition to soluble antigens, B-cell activation by cell-bound antigen is also reduced when
the stimulating cell displays sialic-acid modifications71. So, despite the fact that CD22 is
normally masked, CD22 trans ligands negatively regulate BCR signalling. Indeed, unlike
Ly49A34, sialic-acid-containing trans ligands efficiently recruit CD22 to sites of cell-cell
contact72, indicating that masking is not stable, and that CD22 can switch from a cis- to a
trans-bound state (FIG. 3g). This may be of importance to prevent B-cell activation by cell-
bound self antigens.
Beyond the immune system
Receptors that can bind the equivalent ligand expressed in cis and trans via the same ligand-
binding domain have also been found in biological situations other than the immune system.
For example, ephrin receptors (Ephs) mediate cellular repulsion on interaction with ephrin
ligands expressed by other cells. This permits the sorting of distinct cell types or directs the
growth of axons. Recent data suggest that Eph activity is influenced by ephrins expressed in
the plane of the same membrane73. Indeed, Ephs can bind ephrin ligands expressed in cis via
the ligand-binding domain of the receptor74. Interestingly, cis interactions did not induce Eph
tyrosine kinase activity; rather, signalling by Eph to mediate cellular repulsion was
reduced74. Eph therefore provides the first example of an activating receptor that is subject to
regulation by a ligand interaction in cis.
Prospects and predictions
So far, immunoreceptors that can bind the same ligand in cis and trans are receptors with
inhibitory function. The emerging theme is that cis interactions modify inhibitory signalling.
Whereas trans interactions are always inhibitory, significant differences exist with regard to
the precise role of cis interactions. Cis interactions are required for the inhibitory function of
CD22 and probably also PIRB, whereas they reduce the overall inhibitory capacity of Ly49
receptors. Consequently, cis interactions can serve to increase or decrease the threshold at
which cellular activation signalling produces a biological response.
Following the discovery of inhibitory MHC class I receptors on NK cells, a plethora of
inhibitory immunoreceptors has been identified55. Many of these receptors show wide tissue
distribution whereby ligands may be co-expressed with their receptors on the same cell. It
therefore seems likely that the activity of additional inhibitory receptors and perhaps also
activating receptors is controlled via cis interactions, a possibility that should be considered
along with trans interactions in the study of immunoreceptors.
DATABASES
Entrez Gene: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene
CD22 | CD94 | Ly49A | NKG2D | PIRB
Protein Data Bank: http://www.rcsb.org/pdb/home/home.do
1A6Z | 1MI5 | 1P4L | 1P7Q | 1QO3
FURTHER INFORMATION
Werner Held’s homepage: http://www.lau.licr.org/pages/RG-NKTCDG.htm
Roy Mariuzza’s homepage: https://carb.umbi.umd.edu/user/mariuzza
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Figure 1. Structures of MHC class I receptors
Ribbon diagrams showing the crystal structures of several MHC class I receptors bound to
MHC class I ligands. The α1, α2 and α3 domains of the MHC class I heavy chain are shown
in cyan, β2-microglobulin (β2m) is shown in purple and the MHC-bound peptide is shown in
pink. a | A typical T-cell receptor (TCR)-peptide-MHC-class-I complex is shown (protein data
bank (PDB) ID: 1MI5). The TCR α- and β-chains are shown in red and yellow, respectively.
b | The Ly49C-H2-Kb complex is shown (PDB ID: 1P4L). The two C-type lectin domains
(CTLDs) of Ly49C (shown in red) bind two H2-Kb molecules in a symmetrical arrangement.
The Ly49C dimer is in the ‘open’ conformation. c | Representation of the Ly49A-H2-Dd
complex (PDB ID: 1QO3). The two CTLDs of Ly49A (shown in red) bind a single H2-Dd
molecule in an asymmetrical manner. The Ly49A dimer is in the ‘closed’ conformation. d |
Representation of the LILRB1 (leukocyte immunoglobulin-like receptor B1)-HLA-A2
complex (PDB ID: 1P7Q). The D1 and D2 domains of LILRB1 are shown in red. e | The
transferrin receptor (TfR)-haemochromatosis protein (HFE) complex is shown (PDB ID:
1A6Z). The two subunits of the TfR dimer are shown in red and yellow. HFE, a non-classical
MHC class I molecule, must assume a supine orientation on the cell membrane to bind TfR in
cis. By contrast, the MHC class I molecules in (a-d) are in upright orientations.
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Figure 2. Hypothetical models for trans and cis interactions of ly49 receptors and LILRs with MHC
class I ligands
a| Trans interaction of a Ly49 receptor with two MHC class I molecules, based on the crystal
structure of the Ly49C-H2-Kb complex26. The α1, α2 and α3 domains of the MHC class I
heavy chain are shown in cyan, β2-microglobulin (β2m) is shown in purple and Ly49C is shown
in red. The Ly49C homodimer on the natural killer (NK) cell binds two H2-Kb molecules on
the target cell. The Ly49C-H2-Kb structure does not include the 70-amino-acid stalk regions
that connect the Ly49C homodimer to the NK-cell membrane. The stalks are drawn arbitrarily
here (in green), with horizontal orange bars to indicate disulphide bonds. To bind in trans, the
stalks must adopt a back-folded conformation, as the N-termini of the Ly49C monomers point
away from the NK-cell membrane (Ly49 receptors are type II transmembrane proteins). b |
Cis interaction of Ly49 with MHC class I, based on the structure of the Ly49A-H2-Dd
complex27. The Ly49A homodimer binds one H2-Dd molecule on the NK cell itself. In this
case, the stalks may assume an extended conformation, as the N-termini of the Ly49A
monomers point towards the NK cell. c | Trans interaction of a leukocyte immunoglobulin-
like receptor (LILR) with MHC class I, based on the structure of the LILRB1-HLA-A2
complex40. The LILRB1-HLA-A2 structure includes the two N-terminal immunoglobulin-
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like domains of LILRB1 (D1 and D2), but not its two C-terminal immunoglobulin-like
domains. Domains 3 and 4 (D3 and D4), which link the ligand-binding domains (shown in red)
to the surface of the effector cell, are represented by homology models (shown in yellow). d |
Cis interaction of LILRB1 with MHC class I. To bind to HLA-A2 on the same cell, LILRB1
must bend back on itself, presumably at the connecting region between D2 and D3.
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Figure 3. Physiological role of cis and trans interactions of Ly49A, PIRB and CD22
a | Stable association of Ly49 with H2-Dd in the plane of the natural killer (NK)-cell membrane
(in cis) reduces the pool of Ly49A receptors available to engage H2-Dd on target cells (in
trans). When NK-cell inhibition is restricted, further NK-cell activation, upon the recognition
of the NKG2D (NK group 2, member D) ligand on stressed host cells, results in target-cell
lysis. b | In the absence of Ly49A-H2-Dd interactions in cis, all Ly49A receptors can interact
with H2-Dd in trans, resulting in strong NK-cell inhibition. Limited additional NK-cell
activation may not suffice to induce lysis of stressed host cells. Ly49A association with H2-
Dd in cis decreases the NK-cell activation threshold. c | In the absence of deliberate mast-cell
activation, paired immunoglobulin-like receptor B (PIRB) is constitutively phosphorylated and
associated with MHC class I in the mast-cell membrane, suggesting that cis interactions
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mediate tonic suppression of spontaneous mast-cell degranulation. d | Mast-cell activation by
crosslinking IgE bound to FcεRI (high-affinity Fc receptor for IgE), increases PIRB
phosphorylation and the recruitment of SHP1 (SRC-homology 2 (SH2)-domain-containing
protein tyrosine phosphatase 1). Unlike Ly49A, the inhibitory function of PIRB depends on
cis interaction. PIRB cis interaction increases the threshold for mast-cell activation. e | CD22
is directly and indirectly associated with the B-cell receptor (BCR) by binding sialic-acid-
modified glycoproteins. CD22 cis association dampens basal BCR signalling and prevents
‘spontaneous’ B-cell activation. f | Following B-cell activation with soluble antigen, the
association of CD22 with the BCR is needed for the inhibitory function of CD22. CD22 cis
association increases the threshold for B-cell activation. g | CD22 can switch from a cis- to a
trans-bound state on the encounter of sialic-acid ligand on opposing membranes. The
engagement of CD22 in trans is inhibitory and increases the threshold for B-cell activation.
ITAM, immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor tyrosine-
based inhibitory motif.
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